News update from Physiomics May 2024

19 Jun

News update from Physiomics May 2024

in Blog

Leading mathematical modelling company, supporting oncology drug development.

From us to you – curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.

Top news

Meet with the Physiomics team at BIO International!

Physiomics’ CEO, Peter Sargent, and Head of Business Development, Hayley Close will be joining >20,000 attendees from the biopharma industry in San Diego in June at BIO International.

We look forward to meeting with existing and new clients at the biggest biotechnology networking event of the year!

To meet with us to discuss how we can support your drug development journey, contact us through the partnering system, or email Hayley directly at hclose@physiomics.co.uk.

We look forward to seeing you there!

FDA’s Center for Drug Evaluation and Research (CDER) announces new Quantitative Medicine Centre of Excellence

At Physiomics we have long understood the importance and application of quantitative medicine in the development of new therapeutic drugs. Over the years we have used this expertise to strengthen our clients’ evidence and understanding of their drugs’ behaviour, in both safety and efficacy, to de-risk their development journey.

By establishing the QM Centre of Excellence, an institute dedicated to application and development of quantitative modelling and simulation approaches, the FDA are recognising the need for this expertise in streamlining development of new therapeutic drugs.

The aim of the QM Center of Excellence is “to facilitate and coordinate the continuous evolution and consistent application of QM across CDER”.

Furthermore, this is another signal that the regulators are increasingly encouraging and expecting model-based evidence in regulatory applications and assessments. To learn more about Physiomics’ expertise in quantitative pharmacology and how this can be applied to de-risk decisions and make the development of your therapeutic pipeline more efficient, please get in touch!

For more information on the Quantitative Medicine Centre or Excellence, see here.

GET IN TOUCH